ערך בספרים למניה: Prime Medicine Corp (PRME)

Prime Medicine, Inc. (PRME) faces severe challenges, including zero sales, massive research expenditures, and bioethical uncertainty. However, the development of a unique genome editing method provides protection against dumping and attracts capital, as reflected in the market valuation of the asset, which currently stands at 0.22. An extensive patent portfolio for code "replacement" guarantees future royalties and dominance in the therapy of hereditary pathologies.

Prime Medicine, Inc. (PRME) maintains stability through its available cash reserves dedicated to funding R&D projects. This resource forms the mathematical basis of net assets, determining the book value per share. This metric measures the business's actual balance sheet foundation, excluding market speculation. The trend in total book value per share reflects the burn rate in the absence of revenue. Analyzing this chart allows for an assessment of the company's cash runway.